The long-term management of generalized anxiety disorder: issues and dilemmas.
Accumulating evidence suggests that a large proportion of patients diagnosed with generalized anxiety disorder suffer from a chronic or recurrent condition that is associated with a moderate amount of disability and impairment in quality of life. Acute drug therapy is well studied and appears to be highly effective in providing symptom relief, but relapse/recurrence is high. Little research has been reported that identifies predictors of recurrence or studies the clinical parameters of maintenance drug therapy, including benefit-risk assessments or optimal doses or durations of treatment.
Schweizer
E
E
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Rickels
K
K
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D001569:Benzodiazepines; D002065:Buspirone / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015897:Comorbidity; D003866:Depressive Disorder / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011788:Quality of Life; D012008:Recurrence; D012720:Severity of Illness Index; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D001569:Benzodiazepines; D002065:Buspirone